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Background: Reducing acute respiratory infection burden in children in Africa remains a major priority and
challenge. We analyzed data from population-based infectious disease surveillance for severe acute respiratory illness
(SARI) among children <5 years of age in Kibera, a densely populated urban slum in Nairobi, Kenya.
Methods: Surveillance was conducted among a monthly mean of 5,874 (range = 5,778-6,411) children <5 years old in
two contiguous villages in Kibera. Participants had free access to the study clinic and their health events and utilization
were noted during biweekly home visits. Patients meeting criteria for SARI (WHO-defined severe or very severe
pneumonia, or oxygen saturation <90%) from March 1, 2007-February 28, 2011 had blood cultures processed for
bacteria, and naso- and oro- pharyngeal swabs collected for quantitative real-time reverse transcription polymerase
chain reaction testing for influenza viruses, parainfluenza viruses (PIV), respiratory syncytial virus (RSV), adenovirus, and
human metapneumovirus (hMPV). Swabs collected during January 1, 2009 – February 28, 2010 were also tested
for rhinoviruses, enterovirus, parechovirus, Mycoplasma pneumoniae, and Legionella species. Swabs were collected for
simultaneous testing from a selected group of control-children visiting the clinic without recent respiratory or
diarrheal illnesses.
Results: SARI overall incidence was 12.4 cases/100 person-years of observation (PYO) and 30.4 cases/100 PYO in
infants. When comparing detection frequency in swabs from 815 SARI cases and 115 healthy controls, only RSV
and influenza A virus were significantly more frequently detected in cases, although similar trends neared statistical
significance for PIV, adenovirus and hMPV. The incidence for RSV was 2.8 cases/100 PYO and for influenza A was 1.0
cases/100 PYO. When considering all PIV, the rate was 1.1 case/100 PYO and the rate per 100 PYO for SARI-associated
disease was 1.5 for adenovirus and 0.9 for hMPV. RSV and influenza A and B viruses were estimated to account for
16.2% and 6.7% of SARI cases, respectively; when taken together, PIV, adenovirus, and hMPV may account for >20%
additional cases.
Conclusions: Influenza viruses and RSV (and possibly PIV, hMPV and adenoviruses) are important pathogens to
consider when developing technologies and formulating strategies to treat and prevent SARI in children.* Correspondence: rfbreiman@emory.edu
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Reducing the substantial public health burden of acute
respiratory infection in children in Africa remains a
major priority and an immense challenge [1,2]. Despite
steady advances in characterizing principal etiologies, in-
cidence, and factors contributing to severe respiratory
infection [3,4], knowledge gaps persist [5]. Filling these
gaps is critical to ensuring that limited available public
health resources can be optimally targeted towards feas-
ible, effective interventions. As has been the case for de-
cades [6,7], pneumonia remains a major killer of children
in Africa [8,9]. In 2008, it was estimated that 35 million
cases of pneumonia occur per year in children <5 years
old in Africa [3]; it was the cause of 18% of deaths among
African children, resulting in >750,000 deaths [1].
Many of the formative studies on pneumonia etiology
that provided evidence contributing to design of respira-
tory disease interventions, were conducted over 20 years
ago [10,11]. Much has changed over the past two de-
cades. The epidemiology of predisposing conditions for
pneumonia, such as malaria, HIV and malnutrition, as
well as socioeconomic status, is changing in Africa
[12,13]. Recent introductions of conjugate vaccines for the
two leading bacterial causes of pneumonia, Haemophilus
influenzae type B (Hib) and Streptococcus pneumoniae,
into the Expanded Programme on Immunization (EPI) in
Africa will likely, by reducing the numbers of pneumonias
that they cause, also lead to a shifted set of priority patho-
gens targeted for pneumonia prevention. In addition, new
diagnostic technologies, including the advent of more
readily available, highly sensitive molecular diagnostics,
have enhanced the ability to detect respiratory pathogens
[14,15]. Finally, with massive urbanization in Africa and
advent of densely populated informal settlements or slums
[16], different respiratory pathogen transmission patterns
[17], co-morbidities, and access to health care [18,19]
must be considered when comparing with sparsely popu-
lated rural areas from where most data on pneumonia epi-
demiology and etiology have been collected.
We recently published pneumonia burden and etiology
data from population-based surveillance in rural western
Kenya undertaken from 2007–2010 [20]. To broaden the
knowledge-base and compare etiology and epidemiology,
we analyzed data from our population-based infectious
disease surveillance (PBIDS) site in Kibera, an urban
slum in Nairobi. The rural and urban PBIDS operate
with the same study protocol.
Methods
Study site
CDC and the Kenya Medical Research Institute (KEMRI)
have conducted PBIDS since late 2005 in Kibera, an impo-
verished informal settlement in Nairobi, Kenya with popu-
lation density of 77,000 people per km2 and suboptimalhygiene and sanitation [21,22]. All households in 2 villages,
Gatwikera and Soweto West were offered enrollment. The
mean surveillance population for children <5 years old
was 5,874 (range = 5,778-6,411) children per month
from 2007–2011. Enrollment was continuous since the
project’s beginning. The under-5 mortality rate was 15.1
per 1,000 person-years of observation from 2007–2010
[23]. HIV prevalence in the surveillance area is high
(14.9% in adults ≥18 years in 2008) [24]. Pneumococcal
conjugate vaccine was not yet introduced during this
study period, and vaccine coverage rates for diphtheria-
pertussis-tetanus vaccine (as part of a pentavalent vaccine)
were not available for the study area, but were felt to range
between 60-80% during the study period.
Clinic surveillance
Since March 1, 2007, all enrolled participants received
free medical care for acute illnesses from KEMRI/
CDC-trained clinical staff at Tabitha Clinic (owned by
Carolina for Kibera) located ≤1 km from all surveil-
lance households. Tabitha Clinic sees between 90 and
200 out-patients/day and refers all patients requiring
hospitalization; it does not have in-patient facilities.
Chest radiography was not available through most of
the study period.
The clinic-based case definition for SARI for chil-
dren <5 years old used a modification of the WHO In-
tegrated Management of Childhood Illness algorithm
for severe and very severe pneumonia, defined as a
child with cough or difficulty breathing and any of the
following symptoms or signs: unable to drink/breast-
feed, vomits everything, convulsions, lethargic or un-
conscious, stridor when calm, and lower chest wall
indrawing [25,26], as well as an additional criterion of
oxygen saturation <90%. Blood cultures and nasopha-
ryngeal and oropharyngeal swabs (polyester-tip) were
collected [27] from SARI cases, meeting the above case
definition; however, specimens were not collected from
a substantial proportion of patients during periods of
under-staffing, high patient volume, or if parents/
caretakers did not want to have specimens obtained.
Clinical differences by age group between children
with SARI who were swabbed and not swabbed are
shown in Tables 1 and 2.
Household surveillance
Community interviewers visited enrolled households every
two weeks and questioned surveillance participants using
a standardized questionnaire about recent illnesses, in-
cluding symptoms and health-seeking, and performed a
limited exam on those with symptoms [20]. We defined
SARI from the household visits as cough or difficulty
breathing with either chest indrawing or elevated respira-
tory rate for age [20].
Table 1 Age and gender of children with SARI from
whom respiratory swabs were collected or not collected
Characteristic Number (Row %)
Swabbed (N = 815) Not Swabbed (N = 1777)
Age
<12 m (N = 980) 285 (29.1%) 695 (70.9%)
12-23 m (N = 718) 241 (33.6%) 477 (66.4%)
24-59 m (N = 894) 289 (32.3%) 605 (67.7%)
Total (N = 2592) 815 (31.4%) 1777 (68.6%)
Gender
Male (N = 1369) 411 (30.0%) 958 (70.0%)
Female (N = 1223) 404 (33.0%) 819 (67.0%)
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From January 1, 2009-February 28, 2011, asymptomatic
control-children were enrolled from Tabitha Clinic.
Eligible controls were those who presented with non-
severe illness (i.e. not requiring hospitalization), for
immunizations, or for medicine refills, as described
[20]. Eligible controls could not have had fever, any
respiratory symptoms or diarrhea during the preced-
ing two weeks. Each month, we attempted to enroll
up to six controls <2 years old, and up to six controls
2–4 years old, frequency-matched to cases by known
HIV status; however, this target was not met every
month. Nasopharyngeal and oropharyngeal swabs were
collected from control-children. Ages of controls (mean
2.0, median 1.8) were similar to those of cases (mean 1.7,
median 1.5). Controls were not enrolled if there was a
SARI case-patient from the same household enrolled on
the same day.Table 2 Clinical characteristics of children with SARI from






n % n %
Cough 806 98.9 1747 98.3 0.91
Difficulty Breathing 435 53.3 575 32.4 0.003*
Unable to Drink or Breastfeed 0 0 2 0.1 0.57
Vomits Everything 155 19.0 338 19.0 0.97
Lethargy 28 3.4 93 5.2 0.53
Chest Indrawing 616 75.6 586 33.0 <0.001*
Stridor 21 2.6 80 4.5 0.47
Oxygen Saturation Measured 808 99.1 1755 98.8 0.99
Oxygen Saturation ≤90% 155 19.0 761 42.8 <0.001*
Temperature ≥ 38°C 447 54.9 492 27.7 <0.001*
Temperature ≥ 39°C 162 19.9 142 8.0 0.02*
Death within 14 days following
clinic visit
4 0.5 8 0.5 0.9
*Significant at p < 0.05.Laboratory testing
Clinic staff trained in phlebotomy collected one to
three mL of blood for culture which was inoculated
into commercially-produced blood culture bottles. Bacter-
ial growth was identified using standard methodology,
described previously (BACTEC™ Aerobic Pedi-PLUS™,
Becton Dickinson, Belgium) [28].
Nasopharyngeal and oropharyngeal swabs from cases
and controls were combined into 1 ml of viral transport
media without antibiotics and transported the same day
at 2°C −8°C to KEMRI/CDC laboratories in Nairobi
(<30 minutes by automobile), where each specimen was
divided into four aliquots and stored at −70°C until
testing. Total nucleic acid was extracted from 100 μl of
each specimen using MagMAX Viral RNA Isolation
Kit (Applied Biosystems) and immediately tested with
quantitative real-time reverse transcription polymerase
chain reaction (qRT-PCR) assays for adenovirus, respira-
tory syncytial virus (RSV), human metapneumovirus
(hMPV), influenza types A and B viruses, and parainflu-
enza viruses 1–3 (PIV), as described [20]; A qRT-PCR test
result was considered positive if an exponential fluores-
cence growth curve was detected with an assigned cycle
threshold (CT)value <40.0 [29,30]. Each clinical specimen
was also tested by qRT-PCR for the human ribonuclease
P gene to measure nucleic acid integrity and to con-
firm sample adequacy.
Respiratory swab specimens collected between January
1, 2009 and February 28, 2010 were tested for three add-
itional viruses (rhinovirus, enterovirus, and parechovirus)
and atypical bacteria. Total nucleic acid extracts from
these specimens were shipped on dry ice from Nairobi to
CDC, Atlanta, for testing specifically for the viral patho-
gens; all other testing throughout the study was done at
KEMRI/CDC. qRT-PCR assays for rhinovirus, enterovirus
and parechovirus were performed using previously pub-
lished methodologies [31-33]. The rhinovirus and entero-
virus assays target an area of the 5’ noncoding region of
an area with high sequence similarity between the viruses
that results in some cross-reactivity [34]. Therefore, posi-
tive rhinovirus and/or enterovirus qRT-PCR were reported
together as rhinovirus/enterovirus positive. For atypical
bacteria, multiplex qRT-PCR was performed at KEMRI/
CDC laboratories in Nairobi for Mycoplasma pneumoniae,
Chlamydophila pneumoniae and pan-Legionella species
(atypical bacteria) using published assays [35]. Neither HIV
nor tuberculosis testing was routinely done on children
with SARI at the clinic.
Data analysis
Analyses were performed using SAS (version 9.2, Cary,
NC). Proportions were compared using Pearson’s chi-
square or Fisher’s exact tests (for small cell counts). Rate
ratios and 95% confidence intervals were calculated
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ologists, PEPI, version 4.0x) for crude rates. The Delta
method was used for calculating confidence intervals for
the adjusted rates taking into account the variation in
SARI case numbers, the variation in the adjustment due
to clinic visitation, the variation in estimating the propor-
tion of SARI with pathogen detected, and the variation
in the pathogen attributable fraction (PAF) estimates
(see below) [36].
We compared detection of each virus by qRT-PCR
from swabs between cases and asymptomatic controls
for the period of January 1, 2009, − Feb 28 2011. Odds
ratios (OR) and 95% confidence intervals were calculated
using unconditional logistic regression, adjusting for age
group (0–11, 12–23, 24–59 months) and season when
the swab was taken (December-February, hot and dry;
March-May and September-November, the two rainy
seasons; and June-August, cool). We used ORs to calcu-
late PAF, which estimates the proportion of cases posi-
tive for each virus in which the virus is the likely cause
[20,37,38]. The PAFs, calculated as (OR-1)/OR, were
only calculated for viruses with ORs that were >1.0. For
purposes of this analysis, we assumed the PAF was 1.0
for bacteria detected by blood culture based on the neg-
ligible probability of detection of pathogenic bacteria in
blood of asymptomatic controls.
SARI incidence was calculated as the number of SARI
clinic visits per 100 person-years of observation for the
period March 1, 2007-Feb 28, 2011. Revisits for the same
illness episode (<7 days respiratory symptom free) were
not counted separately. Permanent residence status in
the surveillance area was used to determine person-time
contribution, as described [39]. Adjusted rates of clinic
visitation were calculated accounting for the percentage
of all clinic visits made for SARI that were to the Tabitha
Clinic (the only clinic in the area where standardized
data collection on SARI was done), as opposed to visits
to other area clinics, as determined from the household
visit interviews [21]. We used any clinic visit as a marker
of serious illness, assuming that many illnesses for which
no clinic visit was made were likely less severe. Etiology-
specific adjusted incidence was calculated by applying
the proportions of each etiology to the adjusted inci-
dence of SARI, as shown:
ISARIz ¼ NumSARI= SCV=ACVð Þð Þ  Z=SARIð Þ  PAFð Þ=PYO
100
Where
ISARIz = Incidence of SARI due to pathogen z (per 100
child-years).
NumSARIz = number of SARI cases detected at the
clinic during the study period.SCV/ACV = SARI episodes associated with visiting the
study clinic (SARI Clinic Visits or SCV) divided by
SARI episodes associated with visiting any clinic (any
clinic visits or ACV) (from household visit data).
Z/SARI = Proportion of SARI cases from which
pathogen z is detected.
PAF = (OR-1)/OR.
PYO =Person-years of observation.
Etiology-specific incidence was only calculated for
pathogens with an OR ≥1.0 in the case–control analysis.
We also calculated incidence for pathogens of the same
genus or sub-family (i.e. all influenza viruses and all
parainfluenza viruses).
We calculated a SARI etiologic fraction (SEF) (also
known as population attributable fraction) for each patho-
gen for which incidence was measured (above) [40,41].
For this analysis, SEF is the proportion of SARI cases that
might theoretically be eliminated if the etiology were elim-
inated (assuming a primary role for that etiologic patho-
gen in causing pneumonia). SEF is given as:
SEF ¼ Z=SARIð Þ  PAFð Þ
where Z/SARI and PAF are calculated as in the previous
equation. To attempt to calculate PAFs adjusting for
multiple pathogens (co-infections), we fit a logistic re-
gression model including the pathogens, all pairwise
interaction terms for the pathogens, and age and season-
ality; the outcome variable for the model was case/con-
trol status (1 for case and 0 for control). The RSV and
any parainfluenza interaction variable and the RSV and
adenovirus interaction variable were borderline significant;
all other pathogen interaction variables were non-significant.
However, neither of these interaction variables was synergis-
tic in SARI cases (one pathogen being more likely to be
found when the other is present). The opposite was true–
the second pathogen was less likely to be found in SARI
cases when the other pathogen was present. Therefore, we
simply present PAFs, adjusting only for age and seasonality.
Ethical review
Written informed consent was obtained for data collec-
tion at the clinics and households. The protocol and
consent forms were reviewed and approved by the Insti-
tutional Review Boards of KEMRI (#932) and CDC
(#4566).
Results
A total of 2,592 children <5 years old with SARI were
evaluated at the clinic from March 1, 2007-February 28,
2011; 815 (31.4%) had nasopharyngeal/oropharyngeal
swab specimens collected. Of these, 34.8% were infants
(<12 months old), 29.5% were 12–23 months old, and
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SARI who were swabbed were more likely to be febrile
and to have difficulty breathing and chest indrawing
than children who were not swabbed (Table 2). Among
infants < 1 year of age with SARI, the most commonly
detected viruses in nasopharyngeal/oropharyngeal speci-
mens were rhinovirus/enterovirus (42%), RSV (25%),
adenovirus (20%), and human hMPV (13.7%) (Table 3).
In toddlers 12–23 months old, enterovirus/rhinovirus
(49%), adenovirus (31.5%). RSV (20.3%) and influenzaTable 3 Etiologies of SARI in children < 5 years old, by age gr
<1 year n (%) 12-23
Total patients seen 12445 11838
SARI cases 980 (7.9%) 718 (6
Rate of SARI (per 100 PYO) 30.4 16.7
CFRa for SARI cases 13 (1.3%) 2 (0.3
Blood cultures (BC) done 270 (27.6%) 243 (3
BCs without contaminant 259 (26.4%) 236 (3
S. pneumoniaeb 4 (1.5%) 3 (1.3
H. influenzaeb 0 0
S. aureusb 10 (3.9%) 1 (0.4
Klebsiella pneumoniaeb 0 0
Non-typhi Salmonellab 7 (2.7%) 3 (1.3
Salmonella Typhi 1 (0.4%) 2 (0.8
Other pathogenic bacteriab,c 0 0
Naso/oropharyngeal swabs collected 285 (29.1%) 241 (3
Influenza A 27 (9.4%) 26 (10
Influenza B 4 (1.4%) 6 (2.5
Influenza A or B 31 (10.9%) 31 (12
Respiratory syncytial virus 74 (25.9%) 49 (20
Adenovirus 57 (20%) 76 (31
Parainfluenza virus 1 10 (3.5%) 10 (4.
Parainfluenza virus 2 7 (2.5%) 7 (2.9
Parainfluenza virus 3 31 (10.9%) 27 (11
Any Parainfluenza 46 (16.1%) 43 (17
Human metapneumovirus 39 (13.7%) 23 (9.
Rhinovirus/Enterovirusd 32/76 (42%) 36/73
Parechovirusd 3/76 (4%) 0
Atypical bacteriae 0 0
Positive > =1 virus 204 (71.6%) 182 (7
Positive > =2 virus 71 (24.9%) 67 (27
All data presented as number and percentage in parentheses rounded to the neare
aCase-fatality ratios (CFR) are defined as death in the 30 days following clinic visit fo
bDenominator = uncontaminated blood cultures from 836 patients. Blood culture re
species, or Corynebacteria.
cOther pathogenic bacterium was Escherichia coli.
dRhino/enterovirus, parechovirus, and atypical bacteria were only tested for from
persons <5 years old (76 specimens in <1 year olds, 73 on 12–23 month olds an
epresence of atypical bacteria (Mycoplasma pneumoniae, Chlamydophila pneumonia
March 1, 2007-February 28, 2011.A (10.8%) were the top four viruses detected, and in
children 24–59 months old, the top four pathogens
detected were rhinovirus/enterovirus (53%), adeno-
virus (36.9%), RSV (15.8%), and influenza A (13.4%)
(Table 3). Atypical bacteria were not detected in any
specimens. Overall, a potential pathogen was not de-
tected in respiratory secretions from 29% of cases.
Among 836 uncontaminated blood cultures processed
from children with SARI, a pathogen was isolated from
41 (4.9%). Staphylococcus aureus (1.7%) was the mostoup, in Kibera, Nairobi, Kenya
months n (%) 24-59 months n (%) All cases, n (%)
21385 45668
.1%) 894 (4.2%) 2592 (5.7%)
6.7 12.4
%) 3 (0.3%) 18 (0.7%)
3.8%) 349 (39.0%) 862 (33.3%)
2.9%) 341 (38.1%) 836 (32.3%)
%) 1 (0.3%) 8 (1%)
0 0
%) 3 (0.9%) 14 (1.7%)
0 0
%) 3 (0.9%) 13 (1.6%)
%) 2 (0.6%) 5 (0.6%)
1 (0.3%) 1 (0.1%)
3.6%) 289 (32.3%) 815 (31.4%)
.8%) 39 (13.5%) 92 (11.3%)
%) 11 (3.8%) 21 (2.6%)
.9%) 50 (17.1%) 112 (13.7%)
.3%) 46 (15.8%) 169 (20.7%)
.5%) 108 (36.9%) 241 (29.5%)
1%) 8 (2.7%) 28 (3.4%)
%) 11 (3.8%) 25 (3.1%)
.2%) 19 (6.5%) 77 (9.4%)
.8%) 34 (11.6%) 123 (15.0%)
5%) 35 (11.9%) 97 (11.9%)
(49%) 29/55 (53%) 97/204 (47.5%)
1/55 (1.8%) 4 (2.0%)
0 0
5.5%) 195 (66.8%) 581 (71.0%)
.8%) 83 (28.4%) 221 (27.0%)
st integer.
r SARI episode.
sults discarded if they contained coagulase-negative Staphylococcus, Bacillus
January 1, 2009 – February 28, 2010; 204 swabs were tested among
d 55 in 24–59 month olds).
e, and Legionella species) was assessed by qPCR in 76 np/op swabs.
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(NTS) species (1.6%), Streptococcus pneumoniae (1%) and
SalmonellaTyphi (0.6%) (Table 3).
When comparing detection rates from respiratory swabs
in SARI cases and healthy controls, RSV and influenza A
were significantly associated with being a case (Table 4).
Several viruses (parainfluenza 1 and 3, and hMPV, influ-
enza B, and adenovirus) were associated with adjusted
odds ratios ≥1.5, but the differences between cases and
controls were just outside of statistical significance
(Table 3). All of the other viruses tested were also
found more often in cases than controls with none of
these differences approaching statistical significance.
Having at least one virus detected from swabs was
strongly associated with cases, as was having ≥2 viruses
detected (Table 4).
Taking the proportion of SARI cases from which a
pathogen was detected and the PAF, we calculated the
SARI etiologic fraction (see Methods) attributed to vi-
ruses or groups of viruses. RSV accounted for the highest
etiologic fraction (16.2%) of SARI cases in children <5 years
old, followed by adenoviruses (10.6%), parainfluenza vi-
ruses (7.0%), and influenza A and B combined (6.7%), and
hMPV (6.3%). Since the odds ratios upon which the SARI
etiologic fractions were based were significant only for
RSV and influenza viruses, the etiologic fractions for theTable 4 Naso/oropharyngeal swab test results from cases
and controls






Influenza A 79 (10.8%) 5 (4.3%) 2.57 (1.01-6.52)
Influenza B 19 (2.6%) 1 (0.9%) 3.06 (0.41-23.17)
Influenza A or B 97 (13.3%) 6 (5.2%) 2.71 (1.15-6.39)
Respiratory
syncytial virus
155 (21.2%) 3 (2.6%) 10.15 (3.16-32.58)
Adenovirus 221 (30.2%) 27 (23.5%) 1.51 (0.94-2.42)
Parainfluenza virus 1 26 (3.6%) 1 (0.9%) 4.12 (0.55-30.69)
Parainfluenza virus 2 24 (3.3%) 5 (4.3%) 0.71 (0.26-1.9)
Parainfluenza virus 3 72 (9.8%) 5 (4.3%) 2.31 (0.91-5.85)
Any parainfluenza 115 (15.7%) 10 (8.7%) 1.87 (0.95-3.69)
Human metapneumovirus 91 (12.4%) 7 (6.1%) 2.12 (0.96-4.72)
Atypical bacteria 0 (0%) 0 (0.0%) -
Rhinovirus/
Enterovirus *
97 (47.5%) 24 (50.0%) 0.89 (0.46-1.71)
Parechovirus * 4 (1.9%) 1 (2.1%) 0.73 (0.08-6.85)
Positive > =1 virus 533 (72.9%) 61 (53%) 2.27 (1.51-3.42)
Positive >2 viruses 207 (28.3%) 17 (14.8%) 2.36 (1.36-4.11)
*Rhino/enterovirus, parechovirus and atypical bacteria were only tested among
a subset of patients. 204 swabs cases were tested among cases <5 years old;
48 controls were tested.
**adjusted for age group (0–11, 12–23, 24–59 months) and season during which the
swab was taken.
January 1, 2009, − Feb 28 2011 Kibera, Nairobi Kenya.other three pathogens are point estimates (totalling 23.9%)
and must be viewed with some caution; however, given an
array of co-factors which contribute to the risk of pneumo-
nia, it is conceivable that these pathogens are important in
chains of causation. Overall, 46.8% of SARI cases had an
independently attributable viral etiology. When blood cul-
ture results were included (without regard to blood culture
sensitivity), 51.8% of episodes of SARI had an attributable
pathogen.
The overall incidence of SARI was 12.4 cases/100
PYO; infants had the highest incidence (30.4 cases/100
PYO). The highest pathogen-specific adjusted incidence
rate was with RSV (2.8 cases/100 PYO) (Table 5). The
adjusted incidence for influenza A was 1.0 cases/100
PYO and for influenza A and B combined 1.3 cases/100
PYO (Table 5). The rate for parainfluenza virus-
associated SARI was 1.1 case/100 PYO and the rates for
adenovirus-associated or hMPV-associated SARI were
1.5 and 0.9 case per 100 PYO, respectively.
During the four year study period, RSV primarily oc-
curred during January through April (peaking in March
and April) (Figure 1), a warm and dry, pre-rainy season
in Nairobi. Influenza A was detected year round with a
peak from October through December, a rainy season,
and a smaller peak in June and July, the cold season.
While adenoviruses were detected year round, two peaks
occurred, from January through March, and September
through December. Other pathogens were detected at
low frequency every month.
Discussion
This study characterizes the incidence of major respira-
tory viral pathogens as causes of SARI in children. Be-
cause of insensitivity of diagnostic tests for bacteria, the
roles of key bacterial etiologies were likely underesti-
mated. The rates for SARI are lower than what we ob-
served in a similar study conducted over the same
time interval in a rural, sparsely populated area of Kenya
(Lwak) about 250 km away by road, which also found
that influenza A and RSV were significant contributors
to SARI (20). Both areas have high HIV seroprevalence
in adults (15-20%) (24), but the rural area is holoen-
demic with malaria (which can present as SARI [42]),
whereas in Kibera local transmission of malaria is felt to
be low.
The case definition we used for SARI is similar to defi-
nitions used for severe and very severe pneumonia by
WHO and for ALRI, the only difference being that we
added a clinical criterion of oxygen saturation <90% to
add some specificity for severe disease. Thus, the inci-
dence data from this study should be interpretable
within the context of other reports of severe and very se-
vere pneumonia and of acute lower respiratory infection
in children with the caveat that the study clinic only
Table 5 Incidence of select pathogens associated with SARI case status among children < 5, Kibera, Kenya



















Influenza A 11.2% 290 0.82 354 0.64 227 1.0 (0.4-1.7)
Influenza A and
B combined
13.7% 355 0.82 433 0.64 277 1.3 (0.6-2.0)
Respiratory
syncytial virus
20.7% 537 0.82 654 0.90 589 2.8 (2.4-3.2)
S. pneumoniae 1% 23 0.82 28 1.00 28 0.1 (0.1-0.2)
S. aureus 1.7% 41 0.82 51 1.00 51 0.2 (0.2-0.3)
Non-typhi Salmonella 1.6% 39 0.82 47 1.00 47 0.2 (0.2-0.3)
Salmonella Typhi 0.6% 18 0.82 22 1.00 22 0.1 (0.1-0.2)
Influenza B 2.6% 67 0.82 82 0.57 47 0.3 (0.0-0.5)
Adenovirus 29.5% 765 0.82 932 0.36 336 1.5 (0.1-2.9)
Parainfluenza
virus 1
3.4% 88 0.82 107 0.77 83 0.4 (0.1-0.7)
Parainfluenza
virus 3
9.4% 244 0.82 297 0.55 163 0.8 (0.2-1.4)
Any parainfluenza 15.0% 389 0.82 474 0.46 218 1.1 (0.2-1.9)
Human metapneumovirus 11.9% 308 0.82 376 0.53 199 0.9 (0.3-1.6)
aPathogen-specific number of cases = % SARI (with swabs collected) with specific pathogen detected multiplied by 2,592—i.e. the number of overall SARI cases
(with and without swabs collected).
bAdjusted number of pathogen-specific SARI cases = Pathogen specific number of SARI cases/0.82 (Proportion of all clinic visits for SARI that were to study clinic).
cPAF = Pathogen Attributable Fraction (see methods).
dFinal adjusted number of cases = Adjusted No. of pathogen specific-SARI cases multiplied by PAF.
eRates calculated per 100 person-years of observation.
March 1, 2007-February 28, 2011.
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nearby hospital; therefore, the clinical spectrum likely
differed from studies of hospitalized SARI patients.
However, children with signs of severe illness (like
chest indrawing, difficulty breathing and high fever)
were more likely to be sampled while those with low
oxygen saturation were not.Figure 1 Monthly (aggregate) distribution of viral pathogens, MarchDecades of research have consistently found RSV to be
the most important viral pathogen causing significant
acute respiratory illness in infants and young children
[2,5,10,43]. A recent meta-analysis of published and un-
published data found that the incidence of RSV-associated
severe ALRI has ranged from 10–18 per 1000 children/
year for infants and 3–9 per 1000 per children <5 years of1, 2007-Feb 28, 2011.
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hospital-based surveillance with defined catchment areas
[44]. These rates were much lower than those found in
Alaska and among the Navajo and White Mountain Apa-
che population in the US and in a site in Guatemala [44];
it is unclear whether the differences are due to eco-
logical variations or methodological differences. The
rates from Kibera for RSV-associated SARI, resulting from
active, community-based surveillance, which made it pos-
sible to account for cases missed during clinic surveil-
lance, were slightly higher than the rates from the earlier
African studies, but lower than the rates we found in the
parallel rural study [20]. Our rural study clinic included
in-patients, which increased the likelihood of including
sicker patients, than in Kibera, where very sick patients
may have chosen to go directly to hospital. The rates from
both studies likely underestimate RSV (and other SARI)
incidence because we only adjusted for that portion of
patients who went to a clinic other than the study
clinic; we did not adjust for under-utilization of any
clinical services, which is a factor to consider in both
the urban and rural sites [17,18].
Over the past decade, the number of studies of influ-
enza has accelerated in sub-Saharan Africa [45]; data
from 15 countries from 2006–2010, including Kenya
(but not Kibera) showed that (without controls) 10% of
SARI cases <5 years old had evidence of influenza infec-
tion [46], which was similar to what we observed in
Kibera. A meta-analysis of published and unpublished
global data, including 2008 data from the Kibera site
(among many others), found a rate of influenza associ-
ated ALRI of 14/1000 children <5 years old in devel-
oping countries [47], imputing that 111,500 deaths
due to influenza (range = 21,000-245,000) occurred in
2008. As documented in other tropical environments
[48], influenza in Kibera appeared to be a year-round
phenomenon without a predominant occurrence in
cool months.
Specimens from cases alone would have suggested that
rhinoviruses were the most important viruses for SARI
in all three age groups; however, rhinoviruses were de-
tected more often from control specimens. This study
does not rule out a role for human rhinoviruses in SARI,
however, as nasopharyngeal specimens are not consist-
ently the optimal sample for determining the cause of
lung pathology. A recent outbreak of fatal respiratory in-
fection in infants in Vietnam was attributed to a sub-
clade of a genotypically distinct cluster of rhinoviruses
[49], and earlier reports have documented association of
specific genotypes of rhinoviruses with ALRI [50,51]. We
did not assess the genotype of the rhinoviruses detected
in this study to determine if there were specific rhino-
virus clusters associated with illness when compared
with controls.M. pneumoniae and C. pneumoniae were not detected
in any specimens; their role in SARI in children in the de-
veloping world is unclear. A recent study from Madagascar
detected M. pneumoniae and C. pneumoniae within a
small subset of children with respiratory illness, without a
healthy control group for comparison [52] and a prospect-
ive study in Tunisia suggested that M. pneumoniae was the
cause of >7% of hospitalized pneumonias in children [53].
While our studies and others have consistently shown
that influenza A and RSV are important contributors to
SARI in children, our data also suggest that when con-
sidered together, PIV, adenovirus and hMPV play a
causal role for approximately 24% of SARI cases with
the caveat that statistical significance when comparing
cases and controls was not quite achieved for these viruses.
The 3 viruses are likely important pathogens to consider
when developing technologies and packaging strategies to
prevent severe acute respiratory illness. However, it should
be noted that because of frequent adenovirus infection in
early childhood and persistent shedding, many detections
of adenovirus by rRT-PCR could represent prevalent rather
than incident infections [54].
There appeared to be a broader range of viruses caus-
ing SARI in Kibera when compared with our rural site
in Lwak [20] and with a recent study conducted in rural
Kilifi, Kenya, which also only found significantly greater
detection of RSV when comparing pneumonia cases
with controls [55]. In our rural study, which was con-
ducted for a shorter, overlapping interval, all odds ratios
were ≤1.3 (with wide confidence intervals) for each of
the same viruses tested as in Kibera, except for the odds
ratio associated with infection with PIV-2 (OR = 2.6;95%
CI =0.6-10.0). While it is tempting to hypothesize that
the population density in Kibera when compared to the
rural site (300 people/km2) provides a more dynamic
“melting pot” for virus introduction and spread, we have
insufficient additional evidence to support the notion.
We used blood culture to document invasive bacterial
infection in patients with SARI. The highly specific re-
sults are, nonetheless, very insensitive. No sensitive tests
for S. pneumoniae and other bacterial pathogens are cur-
rently available. However, historical data and vaccine
probe studies [56] have shown that a substantial propor-
tion (10-20%) of SARI was likely due to pneumococcal
infection; thus, the rate we found (shown in Table 3)
substantially underestimates the rate of S. pneumoniae-
associated SARI. Since Hib vaccine is given routinely in
Kenya, Hib was likely not an important contributor to
SARI incidence. We detected NTS and Salmonella
Typhi in blood culture from only a few patients. How-
ever, given the importance of NTS and S. Typhi as
causes of acute febrile illness often with respiratory
symptoms, in some settings [39,57], it is worthwhile to
be aware of their potential role. The impact of these
Breiman et al. BMC Infectious Diseases  (2015) 15:95 Page 9 of 11pathogens may change, especially with urbanization
and growth in slums, which especially appears to in-
crease the risk for typhoid fever [39]. The data from
this study are consistent with a study from South
Africa suggesting that S. aureus may be an important
cause of pneumonia in children [58]; in that study,
there was a potential link to HIV infection. In an urban
setting in Nigeria, S. aureus was the most common cause
of bacteremia in children with pneumonia [59]. More data
are needed to characterize the burden, co-morbidities and
other risk factors for children with S. aureus bacteremia-
associated SARI, recognizing the potential that some of
the microbiological results may represent contamination.
By calculating etiologic fractions for SARI, approxi-
mately one-half of SARI cases are accountable with the
pathogens we studied. If one assumes, based on pneumo-
coccal vaccine probe data [56,60] that approximately 25%
of SARI (based on a 12% reduction in severe pneumonia
and a 50% vaccine efficacy against all pneumococcal sero-
types from vaccine studies) is due to S. pneumoniae, then
up to 75% of SARI episodes might be attributable to a spe-
cific etiologic agent. Thus, we could not attribute illness
to a specific pathogen in at least 25% of cases. The most
likely explanation for this diagnostic gap is insensitivity of
diagnostic tests and type of specimens– nasopharyngeal
and oropharyngeal swabs are not the most efficient tech-
niques for capturing all respiratory viruses [61] and are
not appropriate for detecting key bacterial etiologies of
pneumonia. Timing of specimen collection vis-à-vis peaks
in virologic shedding may also have played role. It is also
likely that pathogens other than the ones we tested for
(possibly including pathogens not yet known) caused a
proportion of these illnesses, and will become important
public health targets in the future as new diagnostic tests
become available and, also, potentially as new pathogens
are recognized. In addition, clinical syndromes, like mal-
aria, can masquerade as pneumonia, thus accounting for a
proportion of the “non-attributable causes.”
There were a number of limitations associated with
the findings of this investigation. We were limited in this
analysis by the small number of controls. This restricted
the precision of our estimates of pathogen attributable
fraction; consequently, we could not confirm the precise
role of several pathogens that may be important contrib-
utors to the burden of SARI. In addition, quantifying the
viral load in respiratory secretions (which we did not do
in this analysis) could potentially identify a threshold of
pathogen load associated with illness versus asymptom-
atic colonization [62,63]. Also, we did not test for other
pathogens that might contribute to the incidence of
SARI, like human coronaviruses, bocaviruses, and others
[64-66]. The subset of children with SARI who were
swabbed were more likely to have several indicators of
more severe illness (like chest indrawing) than childrenwith SARI who were not swabbed, although low oxygen
saturation was more often observed in children who
were not swabbed. Thus, incidence rates of pathogens
which are linked to specific clinical presentations may
have been overestimated. For calculating pathogen-
specific incidence rates of SARI, we used one adjust-
ment factor, based on the proportion of all clinic visits
for SARI that were to the study clinic, because there
was no available approach to make this adjustment by
etiology; however, in reality, study clinic visitation pat-
terns may not have been consistent across etiologies,
since some may be associated with symptoms more
likely to induce a visit to the study clinic, rather than
other clinics in the area. Finally, since our case defini-
tions for SARI did not include apnea, which can be a
severe manifestation of RSV-associated bronchiolitis in
neonates, we likely underestimated the role of RSV in
young infants. Furthermore, the active case detection,
and enhancements within the community to encourage
early treatment, may have reduced mortality from
SARI, and also reduced detection of more severe forms
of the syndrome, probably led to underestimations of
incidence, especially for pathogens most likely to re-
sult in greater clinical severity of illness; thus, our
findings may not be representative of SARI cases stud-
ied elsewhere.
Conclusions
The findings from this study suggest that interventions
focused on preventing influenza A, RSV, and, perhaps a
combination of parainfluenza viruses, adenovirus and
human metapneumoviruses may have substantial impact
on further reducing the burden of respiratory infections
in children in developing countries, adding to the ex-
pected impact of pneumococcal conjugate vaccines,
which are in the process of being introduced in lower in-
come countries in Africa and Asia, and expected to dimin-
ish pneumococcal disease burden [67]. For influenza, a
variety of tools (vaccines and strategies to deliver them)
already exist [68,69]. For several other key viral pathogens,
vaccine development continues to progress [70,71].
Non-etiology-specific interventions like improving hand
hygiene, reducing exposure to smoke in the home [72,73],
and making oxygen available in clinical settings will likely
contribute to reducing severe illness and mortality.
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